Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does GABAPENTIN Cause Benign prostatic hyperplasia? 129 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 129 reports of Benign prostatic hyperplasia have been filed in association with GABAPENTIN (Gabapentin). This represents 0.2% of all adverse event reports for GABAPENTIN.

129
Reports of Benign prostatic hyperplasia with GABAPENTIN
0.2%
of all GABAPENTIN reports
28
Deaths
116
Hospitalizations

How Dangerous Is Benign prostatic hyperplasia From GABAPENTIN?

Of the 129 reports, 28 (21.7%) resulted in death, 116 (89.9%) required hospitalization, and 78 (60.5%) were considered life-threatening.

Is Benign prostatic hyperplasia Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for GABAPENTIN. However, 129 reports have been filed with the FAERS database.

What Other Side Effects Does GABAPENTIN Cause?

Drug ineffective (10,914) Drug hypersensitivity (6,833) Off label use (6,729) Drug ineffective for unapproved indication (5,231) Product use in unapproved indication (4,919) Toxicity to various agents (4,839) Completed suicide (4,111) Dizziness (4,107) Somnolence (3,798) Fatigue (3,791)

What Other Drugs Cause Benign prostatic hyperplasia?

TADALAFIL (596) TAMSULOSIN (304) FINASTERIDE (266) PANTOPRAZOLE (261) PREDNISONE (257) ALBUTEROL (254) ASPIRIN (243) TIOTROPIUM (235) RAMIPRIL (193) AMLODIPINE (179)

Which GABAPENTIN Alternatives Have Lower Benign prostatic hyperplasia Risk?

GABAPENTIN vs GABAPENTIN ENACARBIL GABAPENTIN vs GADAVIST GABAPENTIN vs GADOBENATE DIMEGLUMINE GABAPENTIN vs GADOBUTROL GABAPENTIN vs GADODIAMIDE

Related Pages

GABAPENTIN Full Profile All Benign prostatic hyperplasia Reports All Drugs Causing Benign prostatic hyperplasia GABAPENTIN Demographics